Home › FDA Approves Pediatric Indication for EMEND (aprepitant) Capsules in Combination with Other Antiemetic Agents
 

Keywords :   


FDA Approves Pediatric Indication for EMEND (aprepitant) Capsules in Combination with Other Antiemetic Agents

2015-09-02 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for EMEND (aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor antagonist. Language: English Contact: MerckMedia:Doris Li, 908-740-1903An Phan, 908-255-6325orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: combination agents indication pediatric

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
09.11Atlantic Tropical Weather Outlook
09.11Eastern North Pacific Tropical Weather Outlook
08.11Hurricane Rafael Graphics
08.11Hurricane Rafael Wind Speed Probabilities Number 22
08.11Hurricane Rafael Forecast Advisory Number 22
08.11Hurricane Rafael Public Advisory Number 22
08.11Summary for Hurricane Rafael (AT3/AL182024)
08.11Trump tariffs could cost UK 22bn of exports
More »